Frontlight ResearchEarly access
CompletedPhase 1
Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study
Key facts
- Who runs it
- Quan Dong Nguyen
- Where
- Palo Alto, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 10 people enrolled
- Started
- 3 May 2024
- Ended
- 30 Sept 2025
- Type of study
- Interventional, 3 groups
- Treatments tested
- Laquinimod eye drops
- Record updated
- 2 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (22)Hide the full registry criteria
Who can take part
- Age 18 years or older
- Participants who are capable and willing to provide informed consent and follow study instructions
- Participants who are scheduled to undergo pars plana vitrectomy (PPV)
- Participants with intraocular pressure (IOP) ≥ 5 mmHg and ≤22 mmHg in study eye
- Women who are not pregnant or lactating, are post-menopausal or have undergone a sterilization procedure
Who cannot take part
- Participants with a history of prior intraocular or extraocular surgery within 90 days of study enrollment
- Use of any topical cyclosporine or corticosteroid or other specified (i.e. calcineurin inhibitors) ophthalmic medication in the study eye for any reason within 14 days of enrollment and before the surgery
- Use of medication consisting of a strong or moderate inhibitor of CYP3A4 within 2 weeks of Baseline visit (and during the study)
- Use of medication consisting of a strong inducer of CYP3A4 within 2 weeks of Baseline visit (and during the study)
- Participants with active periocular or ocular infectious disease (e.g., blepharitis, scleritis, or conjunctivitis, keratitis or endophthalmitis)
- Participant with a history of intravitreal steroids administered to the study eye within 90 days of enrollment
- Participants with a history of intravitreal injection of VEGF inhibitors within 30 days of enrollment
- Mild, moderate, or severe hepatic impairment (any of Child-Pugh Score A, B, and C)
- History of HIV disease or other immunodeficiency disorder
- History of acute hepatitis A (IgM positive), hepatitis B, or hepatitis C
- History of organ or bone marrow transplant
- Presence of malignancy under active treatment
- Any other acute or chronic medical condition that would, in the judgment of the study investigators, reasonably preclude participation in the clinical study
- Any condition that would prevent the investigator from acquiring images of the eye as required per protocol
- Moderate or severe renal impairment (GFR ≤60 mL/min)
- Participants with active infectious uveitis
- Already enrolled in a clinical trial
Where in United States
- Byers Eye Institute at Stanford UniversityPalo Alto, United States
About the trial
What the trial wants to find out
The LION Study is a prospective, single-center phase 1 clinical trial to evaluate the safety, and distribution of Laquinimod administered as topical eye drops for two weeks in human participants.
The 3 groups in the trial
- Group 1Treatment being tested
(3 to 6 participants): Participants will receive a dose of Laquinimod as 2 drops once a day (0.6mg per day) in the study eye for 14 days before the surgery.
Treatment: Laquinimod eye drops
- Group 2Treatment being tested
(3 to 6 participants): Participants will receive a dose of Laquinimod as 2 drops twice a day (1.2mg per day) in the study eye for 14 days before the surgery
Treatment: Laquinimod eye drops
- Group 3Treatment being tested
(3 to 6 participants): Participants will receive a dose of Laquinimod as 2 drops three times a day(1.8 mg per day) for 14 days before the surgery.
Treatment: Laquinimod eye drops
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety, Tolerability, and Distribution of Topical Laquinimod Eye Drops , an Innovative ImmunomodulatOr Targeting Aryl hydrocarboN Receptor (AhR): The LION Study
- Record updated
- 2 November 2026